Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris 09:05:55 10/05/2024 pm IST After market 09:22:42 pm
94.33 EUR +1.23% Intraday chart for Sanofi 94.29 -0.04%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
CAC40: beats record despite rising rates and indecisive W-Street CF
Novavax Stock Price More Than Doubles After COVID-19 Vaccine Licensing Deal With Sanofi MT
News Highlights : Top Company News of the Day - Friday at 11 AM ET DJ
CAC40: new all-time high (8,257), after DAX, AEX, FT-100 CF
Novavax Unveils COVID-19 Vaccine Licensing Deal With Sanofi; Shares Soar MT
Trending : Sanofi, Novavax to Develop New Covid-19 Vaccines DJ
Sector Update: Health Care Stocks Edge Higher Premarket Friday MT
Sector Update: Health Care MT
Wall Street Set to Extend Gains on Thursday's Higher-Than-Expect Jobless Claims Report, Lifting US Equity Futures Pre-Bell MT
SANOFI : UBS gives a Buy rating ZD
HEDGE FUND SHAH CAPITAL SAYS NOVAVAX-SANOFI DEAL IS "A STEP IN T… RE
Top Premarket Gainers MT
HEDGE FUND SHAH CAPITAL - NOVAVAX-SANOFI DEAL CONCURS WITH SHAH… RE
Novavax: co-exclusive licensing agreement with Sanofi CF
Indexes already back on top Our Logo
SANOFI : JP Morgan reaffirms its Neutral rating ZD
Novavax Shares Surge on $1.4 Billion Vaccine Licensing Deal with Sanofi DJ
Novavax Unveils Deal With Sanofi to Co-commercialize COVID-19 Vaccine, Develop Novel Medication MT
CAC40: continues its rise, close to its all-time high CF
Sanofi to Acquire Minority Stake in Novavax Under Co-exclusive Licensing Deal for COVID-19 Vaccine MT
Sanofi: co-exclusive licensing agreement with Novavax CF
France's Sanofi in COVID-19 vaccine deal with Novavax - statement RE
Royalty Pharma to Acquire Frexalimab Royalties, Milestones for $525 Million in Cash MT
Sanofi Close to Choosing BNP, BofA for Consumer Health Spinoff Deal MT
Bank of America, BNP Set to Win Lead Roles on Sanofi's Consumer-Healthcare Spin Off MT
Chart Sanofi
More charts
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
93.18 EUR
Average target price
108.1 EUR
Spread / Average Target
+15.97%
Consensus
  1. Stock Market
  2. Equities
  3. SAN Stock
  4. News Sanofi
  5. Sanofi Secures EUR10 Million Exclusivity Deal for Adocia's Diabetes Drug
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW